

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Cannabidiol (Epidiolex)

Notes:

+ AEDs for Lennox Gastaut: felbamate, valproate, topiramate, lamotrigine, rufinamide, clobazam, clonazepam, zonisamide; AEDs for Dravet Syndrome: valproate, clobazam, levetiracetam, topiramate, zonisamide, clonazepam, ethosuximide, stiripentol; AEDs for Tuberous Sclerosis Complex: valproate, vigabatrin, levetiracetam, carbamazepine, clobazam, lamotrigine, oxcarbazepine, topiramate
Significant hepatic impairment: liver function tests (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times upper limit of normal with bilirubin greater than 2 times upper limit of normal

Initiation (new start) criteria and criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-formulary **cannabidiol (Epidiolex)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed by a neurologist
- Patient is 1 year old or older
- Prescribed for seizures associated with Dravet Syndrome **OR** Lennox-Gastaut syndrome **OR** Tuberous Sclerosis Complex
- Patient has failed an adequate trial of, or patient has an allergy or intolerance to at least 2 other antiepileptic medications (AEDs) that are appropriate for diagnosis⁺
- No significant hepatic impairment[#]
- Patient is not using cannabis or other cannabis derivatives

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously. Non-formulary **cannabidiol (Epidiolex)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient is 1 year old or older
- Prescribed for seizures associated with Dravet Syndrome **OR** Lennox-Gastaut syndrome **OR** Tuberous Sclerosis Complex
- Patient has failed an adequate trial of, or patient has an allergy or intolerance to at least 2 other antiepileptic medications that are appropriate for diagnosis⁺
- Patient is not using cannabis or other cannabis derivatives

kp.org

Revised: 03/10/22
Effective: 05/05/22

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Cannabidiol (Epidiolex)

Continued use criteria for patients stable on the medication: Non-formulary **cannabidiol (Epidiolex)** will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed by Neurologist
- Sustained improvement in seizure control (frequency and/or severity) since starting Epidiolex as assessed and documented by neurologist
- No significant hepatic impairment[#]
- Patient is not using cannabis or other cannabis derivatives
- Office visit or telephone visit with neurologist within the past 12 months

kp.org

Revised: 03/10/22
Effective: 05/05/22

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest